Amgen's Maritide Shows Promising 20% Weight Loss in Yearlong Study

Amgen announced that its experimental obesity drug, MariTide, led to an average weight loss of up to 20% in patients over a year without plateauing, according to mid-stage trial results. The drug also showed a 17% weight loss in patients with both obesity and Type 2 diabetes. Despite these results, Amgen's shares fell as the outcomes were at the lower end of Wall Street expectations. The trial's first part tested various dosing regimens, and the second part will assess the durability of weight loss and less frequent dosing. MariTide's unique mechanism involves a peptide antibody conjugate targeting GLP-1 and GIP hormones.